Corporate Presentation
Imetelstat is a First-in-Class Telomerase Inhibitor
Based on Nobel-Prize Winning Science
Potentially powerful mechanism for treating hematologic malignancies
Telomerase is continually
upregulated in malignant cells
Malignant clones
geron
Imetelstat binds to
telomerase, inhibiting
its activity
Upregulated
telomerase
Telomerase
ā
Jua
Imetelstat
Apoptosis of malignant
cells and recovery of
effective hematopoiesis
Apoptotic
malignant
clones
8888
Imetelstat is designed to target malignant clones at their source
and enable recovery of healthy blood cell production
Inhibition of
telomerase
Murati et al, BMC Cancer 2012; Shih et al, Rev Cancer 2012; Ntziachristos et al, Adv Immunol 2013; Vardiman et al, Blood 2009; Kittur et al, Cancer 2007; Anastasi J Hematol
Oncol Clin North Am. 2009; Hiyama et al. J Immunol 1995; Hiyama et al, Br J Cancer 2007; Bruedigam et al, Cell Stem Cell 2014: Mosoyan et al, Leukemia 2017; Wang et al,
Blood Adv 2018; Steensma et al, JCO 2020; Platzbecker et al, ASH 2020; Mascarenhas et al, JCO 2021; Mascarenhas et al, ASH 2018 and 2020 and EHA 2021; Platzbecker,
Santini et al, The Lancet 2023.
Evidence for
potential disease
modification
Clinical efficacy:
durable TI (TD LR-
MDS Ph3);
improved overall
survival (R/R MF
Ph2)
Molecular data:
reductions in
variant allele
frequency (VAF)
and depletion of
mutated abnormal
cells associated
with disease
5View entire presentation